Heron Therapeutics | HRTX - Net Income

Stock Price
1.07
Daily Change
-0.06 -5.31%
Monthly
-15.08%
Yearly
-54.66%
Q1 Forecast
1.15

Heron Therapeutics reported $-4.85M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
ALKERMES USD 49.34M 33.42M Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amarin USD -7.74M 6.4M Sep/2025
ANI Pharmaceuticals USD 32.35M 6.08M Dec/2025
Anika Therapeutics USD -4.87M 16.99M Mar/2025
Arrowhead Research USD 30.81M 54.56M Dec/2025
Eisai JPY 17.18B 7.02B Dec/2025
Emergent BioSolutions USD -261.3M 78.3M Jun/2023
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Insmed USD -328.48M 41.54M Dec/2025
Ligand Pharmaceuticals USD 117.27M 112.43M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Omeros USD -32.23M 23.81M Sep/2024
Pacira USD 1.64M 3.8M Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Surmodics USD -11.54M 3.99M Sep/2024
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Veracyte USD 41.15M 22.01M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025